Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
Six patients with recurrent or progressive anaplastic oligodendroglial tumors after surgical treatment and irradiation were treated with six/seven cycles of intensified PCV: Vincristine (1 mg/m(2)), CCNU (50 mg/m(2)) d.1,15 and procarbazine (75 mg/m(2)) d.2 to 29. If leukocytopenia (< 2.500/microl) or thrombocytopenia (< 75.000/microl) developed, 1 x 10(6) CD34(+) autologous stem cells/ kg body weight were reinfused three days after completion of subsequent cycles. Complete response was seen in 2/6 and partial response in 4/6 patients. Median follow up from time of recurrence was 35 months, progression free survival was 18 to > 39 months and overall survival 23 to > 39 months. We conclude that intensified PCV with stem cell support is feasable in recurrent/progressive anaplastic oligodendroglial tumors and appears to be sufficiently well tolerated to allow further study.
Zander
Thomas
T
Department of Neurology, University Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.
Nettekoven
Willy
W
Kraus
Jürgen A
JA
Pels
Hendrik
H
Ko
Yon D
YD
Vetter
Hans
H
Klockgether
Thomas
T
Schlegel
Uwe
U
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000517:prevention & control; D001932:Brain Neoplasms / Q000188:drug therapy*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced / Q000628:therapy; D008130:Lomustine / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009837:Oligodendroglioma / Q000188:drug therapy*; D011344:Procarbazine / Q000009:adverse effects* / Q000627:therapeutic use*; D016879:Salvage Therapy; D013921:Thrombocytopenia / Q000139:chemically induced / Q000628:therapy; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use*
D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine